Screener
Adaptive Biotechnologies ADPT Immune Medicine Business — Adjusted Ebitda
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept adpt:AdjustedEbitda.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 / MRD | Three Months Ended March 31, 2026 / Immune Medicine | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / MRD | Three Months Ended March 31, 2025 / Immune Medicine(1) | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Other segment items(2) | — | 5,776 | 5,776 | — | 5,153 | 5,153 |
| Add back: | ||||||
| Items to reconcile net income or net loss to Adjusted EBITDA(3) | 8,776 | 5,569 | 14,345 | 8,127 | 5,813 | 13,940 |
| Adjusted EBITDA(3) | 12,138 | (10,360) | 1,778 | (4,111) | (5,106) | (9,217) |
| Items to reconcile to consolidated net loss: | ||||||
| Share-based compensation expense(4) | (9,969) | (9,654) | ||||
| Restructuring expense(5) | (643) | — | ||||
| Impairment of long-lived assets(5) | (347) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's immune medicine business — adjusted ebitda?
- Adaptive Biotechnologies (ADPT) reported immune medicine business — adjusted ebitda of -$10.36M in Q1 2026.
- How has Adaptive Biotechnologies's immune medicine business — adjusted ebitda changed year-over-year?
- Adaptive Biotechnologies's immune medicine business — adjusted ebitda decreased by 102.9% year-over-year, from -$5.11M to -$10.36M.
- What is the long-term trend for Adaptive Biotechnologies's immune medicine business — adjusted ebitda?
- Over 2 years (2022 to 2024), Adaptive Biotechnologies's immune medicine business — adjusted ebitda has grown at a -26.9% compound annual growth rate (CAGR), from -$45.65M to -$24.41M.
- What does immune medicine business — adjusted ebitda mean?
- This metric measures the operational profitability of the Immune Medicine Business segment by excluding interest, taxes, depreciation, amortization, and other non-cash or non-recurring items. It provides a normalized view of the segment's core earnings power and operational efficiency.
Ask your AI about Adaptive Biotechnologies's immune medicine business — adjusted ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude